Abstract: A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.
Abstract: A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.
Abstract: Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
Type:
Application
Filed:
November 16, 2021
Publication date:
April 28, 2022
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins.
Type:
Grant
Filed:
September 11, 2020
Date of Patent:
April 12, 2022
Assignee:
Albert Einstein College of Medicine
Inventors:
Hui B. Sun, Daniel J. Leong, Neil J. Cobelli, David M. Hirsh, John A. Hardin, Karen E. Sperling, Sun J. Kim, David C. Spray, Chandan Guha, Marwa Choudhury
Abstract: The application discloses methods and compositions for inhibiting functions associated with vascular endothelial growth factor-A (VEGF-A). The methods and compositions may involve the use of pan-variant specific aptamers for binding to VEGF-A, and preventing or reducing association of VEGF-A with Flt-1, KDR, or Nrp-1. The methods and compositions may include one or more aptamers that bind to receptor binding face of VEGF-A. The methods and compositions may include one or more aptamers that bind to a receptor binding domain of VEGF-A. The application further provides anti-VEGF-A aptamers for the treatment of ocular diseases or disorders. In some cases, the anti-VEGF-A aptamers may have a stem-loop secondary structure.
Type:
Application
Filed:
January 10, 2020
Publication date:
March 31, 2022
Applicants:
DRIVE THERAPEUTICS LLC, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Carl ERICKSON, Christopher P. RUSCONI, Matthew LEVY, Keith E. MAIER, Sarah E. THACKER, Derek PARKS
Abstract: Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses. Provided is a derivative of a compound or a pharmaceutical salt thereof, wherein the compound comprises a 3?,4-didehydroribose.
Type:
Grant
Filed:
August 21, 2018
Date of Patent:
March 22, 2022
Assignees:
Albert Einstein College of Medicine, The Penn State Research Foundation
Inventors:
Steven C. Almo, Tyler Grove, Anthony Gizzi, Craig E. Cameron, James J. Arnold
Abstract: Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
Type:
Grant
Filed:
June 9, 2020
Date of Patent:
February 22, 2022
Assignees:
MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
Inventors:
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
Type:
Grant
Filed:
June 9, 2020
Date of Patent:
February 8, 2022
Assignees:
MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
Inventors:
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
Type:
Grant
Filed:
June 9, 2020
Date of Patent:
February 8, 2022
Assignees:
MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
Inventors:
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Abstract: Provided herein are small molecule compounds and methods inhibiting human sulfotransferase 1A3 (SULT1A3) using these small molecule compounds. Methods of manufacturing and treatment are also disclosed.
Type:
Application
Filed:
December 10, 2019
Publication date:
January 27, 2022
Applicants:
University of Pittsburgh - Of the Commonwealth System of Higher Education, Albert Einstein College of Medicine
Inventors:
Alexander Deiters, Kristie E. Darrah, Mary Frances Cacace, Ian Cook, Thomas Leyh, Ting Wang
Abstract: Methods and systems for high-throughput Identification of receptor:ligand interactions are provided. Throughout this application various publications are referred to in parentheses. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.
Type:
Grant
Filed:
July 25, 2018
Date of Patent:
January 18, 2022
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Steven C. Almo, Ronald D. Seidel, III, Brandan S. Hillerich, Sarah C. Garrett-Thomson, James D. Love
Abstract: Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
Type:
Grant
Filed:
April 26, 2016
Date of Patent:
January 4, 2022
Assignee:
Albert Einstein College of Medicine, Inc.
Abstract: Methods and systems for obtaining inhibitors of human DNA methyltransferase 1 (DNMT1) are disclosed where the methods involve designing compounds that resemble the DNMT1 transition state.
Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
Type:
Application
Filed:
January 4, 2021
Publication date:
December 16, 2021
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
Abstract: Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
Abstract: Methods and compositions for reducing a ratio of collagen III to collagen I in wounded skin, treating wounds and accelerating healing is provided with a surfactant polymer dressing comprising FL2 siRNA, collagen and a poloxamer.
Type:
Application
Filed:
October 23, 2019
Publication date:
November 18, 2021
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, MICROCURE, INC.
Inventors:
David James SHARP, Brian O'ROURKE, Adam Hildyard KRAMER
Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
Type:
Grant
Filed:
August 10, 2020
Date of Patent:
November 16, 2021
Assignees:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Inventors:
Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
Abstract: Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin:total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.
Type:
Grant
Filed:
July 24, 2018
Date of Patent:
November 9, 2021
Assignees:
ALBERT EINSTEIN COLLEGE OF MEDICINE, KING'S COLLEGE LONDON
Inventors:
John Condeelis, Tony Tsz-Cheong Ng, Gregory Weitsman